Molecular diagnosis in WHO classification of tumours of the central nervous system 2016：a domestic survey and perspectives

Abstract

WHO Classification of Tumours of the Central Nervous System was revised in 2016 for the 4th edition. The new classification recommends that molecular genetic information should be added to histological diagnosis and malignancy grade to achieve an integrated diagnosis in certain tumors of the central nervous system. In this article, we summarize the background information and major points regarding this revision. Currently, an optimal system for molecular genetic diagnosis with standardized test methods and financial support of the National Health Insurance has yet to be established in Japan. In 2017, the Japan Society for Neuro‒Oncology has conducted a survey to understand the domestic status of molecular genetic diagnosis approaches with questionnaires sent to major neurosurgical centers. Here we present the results of this survey to elucidate the current issues related to the molecular diagnosis of central nervous system tumors and discuss future perspectives for improving management in adult patients with gliomas.